文献速递淋巴瘤

霍奇金淋巴瘤和非霍奇金淋巴瘤长期幸存者的后续恶性肿瘤:德国癌症登记数据(1990-2012)的汇总分析

Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
PubMed 文献 · Br J Haematol · 2017-01-20

该研究汇总德国14个联邦州癌症登记数据,纳入1990至2012年间首次原发霍奇金淋巴瘤(HL)或非霍奇金淋巴瘤(NHL)的128 587例患者,计算后续原发恶性肿瘤(SPM)的标准化发病比(SIR)和超额绝对风险(EAR)。与德国一般人群相比,HL幸存者SPM风险显著增加超过两倍(SIR=2.14,EAR=51.87例/10 000人年),NHL幸存者增加1.5倍(SIR=1.48,EAR=55.23)。实体癌SIR分别显著升高1.6倍和1.4倍,初诊时年龄低于30岁者最高(三倍)。

要点

  • HL幸存者SPM风险显著增加超过两倍(SIR=2.14,EAR=51.87例/10 000人年)。
  • NHL幸存者SPM风险增加1.5倍(SIR=1.48,EAR=55.23例/10 000人年)。
  • 初诊时年龄低于30岁者实体癌SIR最高(三倍)。

核心结论

  • 与德国一般人群相比,HL幸存者发生SPM的风险显著增加超过两倍(SIR=2.14,EAR=51.87例/10 000人年),NHL幸存者增加1.5倍(SIR=1.48,EAR=55.23例/10 000人年)。

研究设计与样本

  • 汇总德国14个联邦州癌症登记数据库,纳入1990至2012年间首次原发HL/NHL的128 587例患者,计算SPM的SIR和EAR,并反向计算其他原发癌后发生HL/NHL的SIR。

主要发现

  • HL幸存者SPM风险显著增加超过两倍(SIR=2.14,EAR=51.87例/10 000人年),NHL幸存者增加1.5倍(SIR=1.48,EAR=55.23例/10 000人年)。
  • 实体癌SIR显著升高,HL为1.6倍、NHL为1.4倍,初诊时年龄低于30岁者最高(三倍)。
  • 总体上,唇/口腔、结肠/直肠、肺、皮肤黑色素瘤、乳腺、肾和甲状腺的SIR持续升高。
  • 仅NHL后观察到食管、胃、肝、胰腺、睾丸、前列腺和脑/中枢神经系统的SIR显著升高。
  • 对于某些SPM,HL/NHL诊断后超过10年SIR仍显著升高。

关键数值与推荐

  • HL幸存者SPM的SIR=2.14,EAR=51.87例/10 000人年。
  • NHL幸存者SPM的SIR=1.48,EAR=55.23例/10 000人年。
  • 实体癌SIR:HL为1.6倍,NHL为1.4倍;初诊年龄低于30岁者最高为三倍。
  • HL/NHL与上述多种实体癌之间存在正向相互关联,其中部分似有共同病因机制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The increased risk of subsequent primary malignancies (SPM) in survivors of adult-onset Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains a challenging clinical problem worldwide. The German cancer registry database, pooled from 14 federal states, was used to calculate the standardized incidence ratio (SIR) and excess absolute risk (EAR) of SPM in 128 587 patients registered with first primary HL/NHL between 1990 and 2012. Conversely, SIRs were also calculated for a subsequent HL/NHL following other first cancers. The risk of developing SPM was significantly increased over twofold for HL survivors (SIR = 2·14, EAR = 51·87 cases/10 000 person-years) and 1·5-fold for NHL survivors (SIR = 1·48, EAR = 55·23) compared with the general German population. For solid cancers, SIRs were significantly elevated (1·6- and 1·4-fold; respectively) and were highest (threefold) in patients below 30 years of age upon initial diagnosis. Overall, SIRs were consistently elevated for lip/oral cavity, colon/rectum, lung, skin melanoma, breast, kidney and thyroid. Significantly increased SIRs for oesophagus, stomach, liver, pancreas, testis, prostate, and brain/central nervous system were observed following NHL only. For certain SPM, SIRs remained significantly elevated more than 10 years following HL/NHL diagnosis. Positive reciprocal associations were demonstrated between HL/NHL and several solid cancers mentioned above; for some, common aetiological mechanisms seem plausible.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Baras N, Dahm S, Haberland J, et al. Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012). Br J Haematol. 2017. PMID: 28106907. doi:10.1111/bjh.14530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。